China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has entered into a licensing agreement with UK-headquartered Apollo Therapeutics Group Limited for the development of APL-18881 (HEC88473). This strategic deal grants Apollo exclusive rights to develop and commercialize the drug outside of Greater China, while Sunshine Lake retains the rights within Greater China.
Financial Terms of the Agreement
Under the agreement, Sunshine Lake is set to receive a potential total of USD 938 million, which includes an upfront payment of USD 12 million and up to USD 926 million in development, regulatory, and commercial milestone payments. Additionally, Sunshine Lake will earn tiered royalties ranging from high single to low double digits on net sales.
Drug Profile and Clinical Development
APL-18881 (HEC88473) is a bi-specific fusion protein developed by Sunshine Lake that targets the FGF21 and GLP-1 receptors. It is currently undergoing a Phase II clinical study in China for the treatment of type 2 diabetes. The drug’s innovative mechanism of action has the potential to offer a new therapeutic option for patients with this prevalent metabolic disorder.-Fineline Info & Tech
Leave a Reply